In Reply Thank you for allowing us the opportunity to respond to the commentators’ criticism and clarify the results from our recent report using MABp1 (Xilonix) in patients with moderate to severe plaque psoriasis.
To better clarify our findings, the inclusion criteria for this trial specified that all patients have a diagnosis of plaque psoriasis for 6 months or longer with an affected body surface area of at least 5% and a baseline Psoriasis Area Severity Index (PASI) of at least 12 (NCT01384630). At baseline, this study cohort included 8 patients with plaque psoriasis, 3 of whom also had a history of psoriatic arthritis.
Coleman KM, Gudjonsson JE, Stecher M. Reporting of MABp1 for the Treatment of Psoriasis—Reply. JAMA Dermatol. 2015;151(10):1144. doi:10.1001/jamadermatol.2015.1683